Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke -- a Multi-center, Randomized, Double-blind, Parallel, Multi-doses and Active-controlled Study

NCT04984577 is registered in ClinicalTrials.gov with Nanjing Yoko Biomedical Co., Ltd. as lead sponsor.

NCT NCT04984577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04984577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke -- a Multi-center, Randomized, Double-blind, Parallel, Multi-doses and Active-controlled Study
Lead sponsor
Nanjing Yoko Biomedical Co., Ltd.
Phase
Phase 2
Overall status
Suspended
Start date
November 15, 2021
Completion date
December 31, 2026
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke